The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy

Hallym University Medical Center10 enrolled

Overview

The pathophysiology of central serous chorioretinopathy remains controversial. traditional treatment is laser photocoagulation or photodynamic therapy.Recently Bevacizumab (Avastin, Genetech),an antibody to vascular endothelial growth factor (VEGF),has known antipermeability properties and therefore may theoretically reverse the changes seen in central serous chorioretinopathy. The aim of this study is To investigate concentrations of growth factors and inflammatory cytokines and to report the effect of therapy with bevacizumab in eyes with central serous chorioretinopathy

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Central Serous Chorioretinopathy

Interventions

Eligibility

Sex: ALLMin age: 30 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with a diagnosis of central serous chorioretinopathy * Idiopathic neurosensory retinal elevation demonstrated by optical coherent tomography * Presence of focal leaks at the level of the RPE on fluorescein angiography Exclusion Criteria: * Known side effects of systemic bevacizumab administration * Have a significant cardiovascular or thromboembolic history or were pregnant

Outcomes

Primary Outcomes

Concentrations of growth factors and inflammatory cytokines in Aqueous humor

Time frame: at baseline

Secondary Outcomes

Central macular thickness at optical coherence tomography

Time frame: baseline, 1 month, 3 months, 6 months